Dublin / Buffalo / Houston / Los Angeles / Nashville / Toronto / Raleigh / New York / Chicago / Stockholm / /
Company
AEs / Astex Pharmaceuticals Inc. / mL 150 Weekly / International Working Group / /
Currency
pence / /
Event
FDA Phase / /
Facility
Temple University / University of Southern California / MD Anderson Cancer Center / Sarah Cannon Research Institute / Ohio State University / University of Texas / Princess Margaret Hospital / Roswell Park Cancer Institute / Weill Cornell Medical College / University of Chicago Medical Center / Duke University Medical Center / /
MedicalCondition
Cancer / Myelodysplastic syndromes / pain / High Risk Myelodysplastic Syndromes / Stand Up to Cancer / acute myeloid leukemia / /
MusicGroup
Nausea / /
Organization
Princess Margaret Hospital / World Health Organization / Sarah Cannon Research Institute / American Society of Hematology / University of Southern California / FDA / The Ohio State University / Columbus / Temple University / Philadelphia / Center for Blood Cancers / Weill Cornell Medical College / European Hematology Association / Duke University Medical Center / Roswell Park Cancer Institute / USC Keck School of Medicine / University of Texas / University of Chicago Medical Center / /
Person
Sue Naim / Yong Hao / Karen Yee / Jean Pierre Issa / Katherine Walsh / Ann Intern Med / Patricia Kropf / Elizabeth Griffiths / Gail Roboz / Lynne A. Bui / Mohammad Azab / Raoul Tibes / Michael Savona / Mayo Clinic Arizona / David Rizzieri / Wendy Stock / /
Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA)